EPB41L2

Across TCGA pan-cancer cohorts, EPB41L2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EPB41L2 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EPB41L2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EPB41L2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where EPB41L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.822	0.564	.020	28	view →
LUAD	DFS	Tertile	All	0.829	0.474	.002	22	view →
CCRCC	OS	Median	III,IV	0.104	0.989	.003	14	view →
COAD	DFS	Median	III,IV	1.000	0.841	.041	12	view →
OV	DFS	Tertile	All	0.639	0.973	.028	8	view →
UCEC	DFS	Median	All	0.936	1.000	.022	4	view →
LSCC	OS	Tertile	All	0.712	1.000	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EPB41L2–PDAC (DFS)

Open the PDAC breakdown →